TEVA in the 13F filings
Teva Pharmaceutical Inds LTD · CUSIP 881624209
- Quarter end
- 31 Mar 2025
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 7 May 2025
- Managers listing it
- 12
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q4 2024 and Q1 2025; 12 listed it in both
- Shares listed
- 130,972,550
- combined, among listed positions
- Reported value
- $2.0bn
- combined, at the quarter end
Among the 95 comparable managers: 7 buyers (opened or added shares) and 6 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing TEVA in Q1 2025
12 of 12 holders
Largest increases and reductions, by shares
Increases
- Glenview Capital Management LLCexisting position · 14,778,641 shares now+6,322,317
- Viking Global Investors LPexisting position · 10,125,478 shares now+3,621,993
- Holocene Advisors LPexisting position · 4,020,628 shares now+851,215
- Fidelity (FMR LLC)existing position · 82,742,016 shares now+758,785
- Tudor Investment Corpexisting position · 697,457 shares now+247,456
Reductions
- Renaissance Technologies LLCexisting position · 5,301,245 shares now-1,674,973
- Millennium Management LLCexisting position · 5,495,489 shares now-1,046,700
- Janus Henderson Group Ltdexisting position · 6,078,241 shares now-659,384
- ARK Investment Management LLCexisting position · 90,253 shares now-10,190
New positions and exits
New (0)
No new position among listed positions.
Exited (2)
- Arrowstreet Capital LPwas $154m
- Marshall Wace LLPwas $114m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 14 | $5.5bn | n.a. | n.a. |
| Q3 2013 | 16 | $5.9bn | n.a. | n.a. |
| Q4 2013 | 17 | $5.4bn | n.a. | n.a. |
| Q1 2014 | 24 | $7.7bn | n.a. | n.a. |
| Q2 2014 | 24 | $7.3bn | n.a. | n.a. |
| Q3 2014 | 25 | $7.4bn | n.a. | n.a. |
| Q4 2014 | 25 | $8.1bn | n.a. | n.a. |
| Q1 2015 | 25 | $8.7bn | n.a. | n.a. |
| Q2 2015 | 26 | $8.2bn | n.a. | n.a. |
| Q3 2015 | 23 | $8.4bn | n.a. | n.a. |
| Q4 2015 | 25 | $12.8bn | n.a. | n.a. |
| Q1 2016 | 27 | $10.3bn | n.a. | n.a. |
| Q2 2016 | 22 | $8.8bn | n.a. | n.a. |
| Q3 2016 | 25 | $7.9bn | n.a. | n.a. |
| Q4 2016 | 19 | $6.6bn | n.a. | n.a. |
| Q1 2017 | 22 | $5.9bn | n.a. | n.a. |
| Q2 2017 | 14 | $6.2bn | n.a. | n.a. |
| Q3 2017 | 15 | $3.0bn | n.a. | n.a. |
| Q4 2017 | 14 | $4.1bn | n.a. | n.a. |
| Q1 2018 | 13 | $4.8bn | n.a. | n.a. |
| Q2 2018 | 18 | $7.0bn | n.a. | n.a. |
| Q3 2018 | 18 | $6.3bn | n.a. | n.a. |
| Q4 2018 | 19 | $4.9bn | n.a. | n.a. |
| Q1 2019 | 14 | $4.7bn | n.a. | n.a. |
| Q2 2019 | 14 | $2.8bn | n.a. | n.a. |
| Q3 2019 | 11 | $2.0bn | n.a. | n.a. |
| Q4 2019 | 9 | $2.9bn | n.a. | n.a. |
| Q1 2020 | 14 | $2.0bn | n.a. | n.a. |
| Q2 2020 | 12 | $2.8bn | n.a. | n.a. |
| Q3 2020 | 7 | $2.1bn | n.a. | n.a. |
| Q4 2020 | 5 | $2.2bn | n.a. | n.a. |
| Q1 2021 | 8 | $2.6bn | n.a. | n.a. |
| Q2 2021 | 7 | $2.1bn | n.a. | n.a. |
| Q3 2021 | 6 | $1.7bn | n.a. | n.a. |
| Q4 2021 | 4 | $1.1bn | n.a. | n.a. |
| Q1 2022 | 9 | $1.4bn | n.a. | n.a. |
| Q2 2022 | 11 | $913m | n.a. | n.a. |
| Q3 2022 | 11 | $1.4bn | n.a. | n.a. |
| Q4 2022 | 11 | $1.7bn | n.a. | n.a. |
| Q1 2023 | 8 | $1.3bn | n.a. | n.a. |
| Q2 2023 | 10 | $184m | n.a. | n.a. |
| Q3 2023 | 13 | $384m | n.a. | n.a. |
| Q4 2023 | 10 | $373m | 8 | 3 |
| Q1 2024 | 16 | $666m | 8 | 6 |
| Q2 2024 | 22 | $1.8bn | 13 | 7 |
| Q3 2024 | 22 | $2.3bn | 9 | 12 |
| Q4 2024 | 18 | $3.0bn | 8 | 11 |
| Q1 2025 | 12 | $2.0bn | 7 | 6 |
| Q2 2025 | 11 | $1.8bn | 6 | 5 |
| Q3 2025 | 14 | $964m | 9 | 4 |
| Q4 2025 | 16 | $2.1bn | 18 | 22 |
| Q1 2026 | 14 | $2.0bn | 20 | 19 |
| Q2 2026 | 14 | $2.4bn | 18 | 16 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
TEVA and LLY →TEVA and JNJ →TEVA and VRTX →Choose a stock to compare with TEVA →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own TEVA, latest filings →Back to the 13F Explorer →